Portage Biotech Analyst Ratings
Portage Biotech Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/31/2023 | 313.53% | Cantor Fitzgerald | → $11 | Reiterates | Overweight → Overweight |
| 08/02/2023 | 238.35% | HC Wainwright & Co. | $21 → $9 | Maintains | Buy |
| 08/01/2023 | 313.53% | Cantor Fitzgerald | $16 → $11 | Maintains | Overweight |
| 12/01/2022 | 689.47% | HC Wainwright & Co. | $22 → $21 | Maintains | Buy |
| 11/30/2022 | 576.69% | Oppenheimer | $26 → $18 | Maintains | Outperform |
| 09/20/2022 | 727.07% | HC Wainwright & Co. | $32 → $22 | Maintains | Buy |
| 03/07/2022 | 1103.01% | HC Wainwright & Co. | → $32 | Initiates Coverage On | → Buy |
| 09/21/2021 | 1027.82% | Oppenheimer | → $30 | Initiates Coverage On | → Outperform |
| 09/02/2021 | 1403.76% | B. Riley Securities | → $40 | Initiates Coverage On | → Buy |
| 08/19/2021 | 1215.79% | Cantor Fitzgerald | → $35 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月31日 | 313.53% | 康託·菲茨傑拉德 | →$11 | 重申 | 超重→超重 |
| 08/02/2023 | 238.35% | HC Wainwright公司 | $21→$9 | 維護 | 買 |
| 08/01/2023 | 313.53% | 康託·菲茨傑拉德 | $16→$11 | 維護 | 超重 |
| 12/01/2022 | 689.47% | HC Wainwright公司 | $22→$21 | 維護 | 買 |
| 2022年11月30日 | 576.69% | 奧本海默 | $26→$18 | 維護 | 跑贏大盤 |
| 09/20/2022 | 727.07% | HC Wainwright公司 | $32→$22 | 維護 | 買 |
| 03/07/2022 | 1103.01% | HC Wainwright公司 | →$32 | 開始承保 | →購買 |
| 2021/09/21 | 1027.82% | 奧本海默 | →$30 | 開始承保 | →跑贏大盤 |
| 09/02/2021 | 1403.76% | B.萊利證券 | →$40 | 開始承保 | →購買 |
| 2021/08/19 | 1215.79% | 康託·菲茨傑拉德 | →$35 | 開始承保 | →超重 |
What is the target price for Portage Biotech (PRTG)?
Porage Biotech(PRTG)的目標價是多少？
The latest price target for Portage Biotech (NASDAQ: PRTG) was reported by Cantor Fitzgerald on August 31, 2023. The analyst firm set a price target for $11.00 expecting PRTG to rise to within 12 months (a possible 313.53% upside). 6 analyst firms have reported ratings in the last year.
康託·菲茨傑拉德於2023年8月31日報道了Porage Biotech(納斯達克：PRTG)的最新目標價。這家分析公司將目標價定為11美元，預計PRTG將在12個月內上漲(可能上漲313.53%)。6家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Portage Biotech (PRTG)?
波蒂奇生物技術公司(PRTG)的最新分析師評級是多少？
The latest analyst rating for Portage Biotech (NASDAQ: PRTG) was provided by Cantor Fitzgerald, and Portage Biotech reiterated their overweight rating.
波蒂奇生物技術公司(納斯達克代碼：PRTG)的最新分析師評級由康託·菲茨傑拉德提供，波蒂奇生物技術公司重申其增持評級。
When is the next analyst rating going to be posted or updated for Portage Biotech (PRTG)?
Porage Biotech(PRTG)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Portage Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Portage Biotech was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與波蒂奇生物技術公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Porage Biotech的上一次評級是在2023年8月31日提交的，所以你應該預計下一次評級將在2024年8月31日左右的某個時候公佈。
Is the Analyst Rating Portage Biotech (PRTG) correct?
分析師對Porage Biotech(PRTG)的評級正確嗎？
While ratings are subjective and will change, the latest Portage Biotech (PRTG) rating was a reiterated with a price target of $0.00 to $11.00. The current price Portage Biotech (PRTG) is trading at is $2.66, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Porage Biotech(PRTG)評級被重申，目標價在0.00美元至11.00美元之間。Porage Biotech(PRTG)目前的交易價格為2.66美元，在分析師的預測範圍內。